Short-acting Beta Agonists Market Size & Share, by Dosage Form (Injectable, Solution, Tablet, Syrup); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores); Application (Asthma, Chronic Obstructive Pulmonary Disease) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5820
  • Published Date: Mar 05, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Short-acting Beta Agonists Market size is expected to reach USD 2.07 Billion by the end of 2036, growing at a CAGR of 9% during the forecast period, i.e. 2024-2036. In the year 2023, the industry size of short-acting beta agonists was USD 736 Million. The escalating prevalence of respiratory disorders worldwide is propelling the market’s growth. With 454.6 million cases (417.4–499.1) worldwide, chronic respiratory disorders ranked as the third most common cause of mortality in 2019. They were responsible for 4.0 million deaths (95% uncertainty interval 3.6–4.3) worldwide. As conditions like asthma and chronic obstructive pulmonary disease(COPD) become more widespread, the demand for quick-relief medications, such as SABAs, continues to surge. As observed by Research Nester analysts, globally, the prevalence of COPD was predicted to be 10.6% in 2020 for both males and females, or 480 million cases. This driver is fuelled by environmental factors, lifestyle changes, and an aging population, necessitating effective bronchodilators for immediate symptom relief. As a result, pharmaceutical companies are witnessing increased demand for SABAs, positioning them as a pivotal solution in addressing the rising global burden of respiratory diseases.

In addition, when it comes to death rates, chronic obstructive pulmonary disease (COPD) is ranked third worldwide. The increasing prevalence of lung illnesses worldwide is predicted to drive short-acting beta agonists market expansion. People who currently reside in or were raised in urban regions are more prone to experience these illnesses.


Short-acting Beta Agonists Market
Get more information on this report: Request Free Sample PDF

Short-acting Beta Agonists Market: Growth Drivers and Challenges

Growth Drivers

  • Increased Awareness and Diagnosis of Respiratory Conditions- Growing awareness about respiratory health, coupled with improved diagnostic capabilities, leads to early detection and treatment of respiratory disorders. This increased awareness among both healthcare professionals and the general population drives the demand for SABAs as a crucial component of managing acute respiratory symptoms.
  • Technological Advancements in Inhalation Devices- Ongoing advancements in inhalation device technologies contribute to the growth of the SABA market. Improved and user-friendly inhalers enhance the efficiency and ease of medication delivery, promoting patient adherence. Innovations such as smart inhalers and breath-actuated devices further enhance the precision and effectiveness of Short-acting Beta Agonists administration.
  • Patient-Centric Treatment Approaches- The shift towards patient-centric healthcare approaches emphasizes personalized treatment plans. In total, 60.9% (95% CI 57.1%–64.5%) of patients had care that was focused on their needs. Short-acting Beta Agonists, known for their rapid onset of action and immediate relief, align with this trend, as healthcare providers increasingly prescribe respiratory drugs tailored to individual patient needs, contributing to the short-acting beta agonists market growth.

Challenges

  • Stringent Regulatory Approval Processes- The regulatory hurdles associated with gaining approvals for new Short-acting Beta-Agonists formulations or delivery devices can be time-consuming and costly. Stringent regulations can delay market entry for novel products, hindering innovation and potentially limiting the variety of treatment options available to patients.
  • The availability of generic versions of Short-acting Beta-Agonists poses a challenge to the market growth.
  • SABA side effects may affect adherence. Safer formulations, monitoring, and research are crucial for short-acting beta agonists market confidence.

Short-acting Beta Agonists Market: Key Insights

Base Year

2023

Forecast Year

2024-2036

CAGR

~ 9%

Base Year Market Size (2023)

~ USD 736 Million

Forecast Year Market Size (2036)

~ USD 2.07 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Short-acting Beta Agonists Segmentation

Dosage Form (Injectable, Solution, Tablet, Syrup)

The solution segment is predicted to account for 42% share of the global short-acting beta agonists market. The segment’s dominance is primarily due to the nature of respiratory conditions like asthma and COPD, where direct delivery to the lungs provides rapid relief. Between 2001 and 2021, the prevalence of adult asthma increased from 6.9% to 8.0%. Inhalable forms offer a quick onset of action, targeting the affected airways directly. While injectable forms, tablets, and syrups may have their applications, inhalable solutions and aerosols are generally preferred for their effectiveness, convenience, and reduced systemic side effects. Patients find inhalable forms more user-friendly and compliant, contributing to their widespread adoption. Additionally, advancements in inhalation device technology further enhance the appeal of these dosage forms, reinforcing their anticipated majority market share.

Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores)

Retail pharmacies segment is anticipated to hold the majority of the revenue share in the global short-acting beta agonists market. This is attributed to the widespread accessibility of retail pharmacies, making SABA medications readily available to a larger patient population. Retail pharmacies offer convenience, ease of access, and personalized consultation services, promoting patient adherence to respiratory treatments. Additionally, the established presence of retail chains and their ability to provide immediate relief medications aligns with the urgent and episodic nature of conditions like asthma, contributing to the expected dominance of this distribution channel.

Our in-depth analysis of the global short-acting beta agonists market includes the following segments:

        Dosage Form

  • Injectable
  •  Solution
  •  Tablet
  •  Syrup

        Distribution Channel

  • Hospital Pharmacies
  •  Retail Pharmacies
  •  Online Pharmacies
  •  Drug Stores

          Application

  • Asthma
  • Chronic Obstructive Pulmonary Disease

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Short-acting Beta Agonists Industry - Regional Synopsis

North American Market Forecast

North America region is estimated to dominate the global short-acting beta agonists market, accounting for 35% of the revenue share. The region's growth is attributed to the presence of key players in the region. The market is influenced by factors such as the increasing prevalence of respiratory disorders, advancements in inhalation technology, and a growing awareness of respiratory health. Regulatory approvals, generic competition, and regional healthcare policies significantly impact market dynamics. As a crucial component of respiratory care, the North American Short-acting Beta-Agonists market continues to evolve with a focus on innovation, accessibility, and patient-centric solutions. For instance, in the United States, chronic lung diseases such as asthma and COPD, which encompass emphysema and chronic bronchitis, affect about 34 million individuals.

European Market Statistics

European short-acting beta agonists market is estimated to hold a significant revenue share. The market for Short-acting Beta Agonists (SABAs) is influenced by a variety of factors, including the growing prevalence of respiratory disorders, advancements in inhalation technologies, and regulatory approvals. Other factors such as generic competition, regional variations, and healthcare policies also impact market trends. The European SABA market is highly focused on innovation in inhalation therapy and patient-centric solutions. With an emphasis on improving respiratory health and enhancing treatment accessibility, the market is constantly evolving to meet the diverse needs of patients across the region. This focus on innovation and patient-centric solutions has helped to establish Europe as a leader in the global SABAs market.

Research Nester
Short-acting Beta Agonists Market Size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Short-acting Beta Agonists Landscape

top-features-companies

    Bayer AG

    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
    • F. Hoffmann-La Roche Ltd  
    • GlaxoSmithKline plc.
    • Cipla Inc. 
    • Merck & Co., Inc.
    • Schering-Plough Corporation
    •  AstraZeneca
    • Johnson & Johnson Services, Inc.

In-the-news

In The News

  • FDA approved Airsupra inhalation aerosol for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of asthma attacks in patients 18 years and older. It is the first combination of an inhaled corticosteroid and a short-acting beta-agonist to be approved in the U.S. and the first product containing an ICS to be approved in the U.S. as a reliever treatment for asthma.
  • Bayer has acquired Blackford Analysis Ltd, a global imaging AI platform and solutions provider. Blackford's clinical application ecosystem for imaging and analytics is now a wholly-owned subsidiary of Bayer, but Blackford will continue to operate independently.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 5820
  • Published Date: Mar 05, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The rising prevalence of respiratory disorders and diagnosis rate, increasing investments in research and development activities, and rising patient-centric approaches are some of the major drivers for the Short-acting Beta-Agonists Market.

The market size of Short-acting Beta Agonists is anticipated to attain a CAGR of 9% over the forecast period, i.e., 2024-2036.

The major players in the market are Teva Pharmaceutical Industries Ltd., Viatris Inc., F.Hoffmann-La Roche Ltd, GlaxoSmithKline plc., Cipla Inc., Merck & Co., Inc., Schering-Plough Corporation, AstraZeneca, Johnson & Johnson Services, Inc., Takeda Pharmaceutical Company Limited and others.

The Solutions segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Short-acting Beta Agonists Market Report Scope
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying